Grünenthal GmbH

Grünenthal GmbH is an international pharmaceutical company headquartered in Aachen, Germany, specializing in pain management therapies and novel medicines. As a fully integrated global pain management specialist, the company develops and commercializes innovative prescription drugs across key indication areas, including peripheral neuropathic pain, chronic pain, and oncology. Its established brand portfolio features widely recognized prescription medicines such as Qutenza, Vimovo, Versatis, Zomig, Nexium, Crestor, and Moventig. The company operates state-of-the-art manufacturing facilities across Europe and Latin America, providing contract manufacturing services and active pharmaceutical ingredient supply to industry partners. Grünenthal maintains an active R&D pipeline focused on sensory biology, neuroinflammation, and genetic medicine capabilities to address critical unmet medical needs. With commercial presence in 28 countries and products sold in around 100 markets globally, the company serves healthcare professionals, health systems, and pharmaceutical partners. Through targeted mergers and acquisitions and research partnerships, Grünenthal continues to expand its pain management and specialty healthcare offerings.